Alteogen will receive an up front & additional fees upon achievement of development, regulatory & sales milestones along with royalties on sales of the commercialized product
Sandoz to get the global rights to use Alteogen’s ALT-B4, a novel hyaluronidase derived developed using Hybrozyme technology to develop & commercialize the SC version of a Sandoz biosimilar product & also obtain an option to license the Hybrozyme technology for 2 products
Alteogen will be responsible for the regulatory, development & commercial supply of ALT-B4 to Sandoz. At the time of each option’s exercise, both companies will negotiate separate agreements for 2 option products & responsible for an additional products that Sandoz may decide to develop
Ref: Businesswire | Image: Alteogen
